ATE407694T1 - Methode zur beschleunigung der schleimauflöserate - Google Patents

Methode zur beschleunigung der schleimauflöserate

Info

Publication number
ATE407694T1
ATE407694T1 AT03018789T AT03018789T ATE407694T1 AT E407694 T1 ATE407694 T1 AT E407694T1 AT 03018789 T AT03018789 T AT 03018789T AT 03018789 T AT03018789 T AT 03018789T AT E407694 T1 ATE407694 T1 AT E407694T1
Authority
AT
Austria
Prior art keywords
muccus
accelerating
dissolving
rate
muccus dissolving
Prior art date
Application number
AT03018789T
Other languages
English (en)
Inventor
Roderick Hall
Christopher T Poll
Benjamin B Newton
William J A Taylor
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE407694T1 publication Critical patent/ATE407694T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT03018789T 1998-12-22 1999-12-22 Methode zur beschleunigung der schleimauflöserate ATE407694T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21891398A 1998-12-22 1998-12-22
US44196699A 1999-11-17 1999-11-17

Publications (1)

Publication Number Publication Date
ATE407694T1 true ATE407694T1 (de) 2008-09-15

Family

ID=26913378

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99963636T ATE254473T1 (de) 1998-12-22 1999-12-22 Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate
AT03018789T ATE407694T1 (de) 1998-12-22 1999-12-22 Methode zur beschleunigung der schleimauflöserate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99963636T ATE254473T1 (de) 1998-12-22 1999-12-22 Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate

Country Status (13)

Country Link
US (1) US20070086956A1 (de)
EP (2) EP1140150B1 (de)
JP (2) JP3819239B2 (de)
CN (1) CN1229138C (de)
AR (1) AR030257A1 (de)
AT (2) ATE254473T1 (de)
AU (1) AU758832B2 (de)
CA (1) CA2356404C (de)
DE (2) DE69912988T2 (de)
DK (2) DK1140150T3 (de)
ES (2) ES2209542T3 (de)
TW (1) TWI249406B (de)
WO (1) WO2000037099A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
CN1332715C (zh) * 2003-09-09 2007-08-22 王继峰 蛋白酶抑制剂在制备预防和治疗肺部疾病的药物中的用途
EP1586587A1 (de) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Zusammensetzungen und Verfahren zum Nachweis der Angiogenese
GB0411145D0 (en) * 2004-05-19 2004-06-23 Imp College Innovations Ltd Protease inhibitors and their therapeutic applications
CN100408094C (zh) * 2005-08-29 2008-08-06 吉林圣元科技有限责任公司 蛋白酶抑制剂在保护肝细胞功能中的应用
WO2008036293A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
US20150174193A1 (en) * 2012-05-25 2015-06-25 Inserm Agents for treating cystic fibrosis
JP2016204360A (ja) 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1992015605A2 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ES2066033T3 (es) * 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
RU2054180C1 (ru) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
JPH07509229A (ja) * 1992-07-13 1995-10-12 コルバス・インターナショナル、インコーポレイテッド ウシ膵トリプシン阻害因子から誘導される因子Ｘａの阻害因子
US5436153A (en) * 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
AU5684594A (en) * 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE69533472T2 (de) * 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
DE69632435T2 (de) * 1995-07-24 2005-05-12 Mitsubishi Chemical Corp. Inhibitor des Hepatozytwachstumsfaktoraktivators
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
WO1997033996A2 (en) * 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance

Also Published As

Publication number Publication date
DE69939559D1 (de) 2008-10-23
ES2318075T3 (es) 2009-05-01
CN1334743A (zh) 2002-02-06
CA2356404C (en) 2010-03-30
JP2006232810A (ja) 2006-09-07
CA2356404A1 (en) 2000-06-29
DE69912988D1 (de) 2003-12-24
DE69912988T2 (de) 2004-11-11
EP1140150B1 (de) 2003-11-19
ES2209542T3 (es) 2004-06-16
DK1140150T3 (da) 2004-03-22
CN1229138C (zh) 2005-11-30
EP1374891B1 (de) 2008-09-10
AR030257A1 (es) 2003-08-20
WO2000037099A3 (en) 2000-10-26
ATE254473T1 (de) 2003-12-15
AU758832B2 (en) 2003-04-03
WO2000037099A2 (en) 2000-06-29
EP1140150A2 (de) 2001-10-10
EP1374891A1 (de) 2004-01-02
US20070086956A1 (en) 2007-04-19
JP3819239B2 (ja) 2006-09-06
AU1987800A (en) 2000-07-12
DK1374891T3 (da) 2009-01-26
JP2002532558A (ja) 2002-10-02
TWI249406B (en) 2006-02-21

Similar Documents

Publication Publication Date Title
ATE427102T1 (de) Verfahren zur festkírperkristallisierung
DE69930540D1 (de) Verfahren zur herstellung von silalkylen-siloxancopolymeren
DE69916400D1 (de) Verfahren zur selektiven Entfernung von Nitrilen
DE59913665D1 (de) Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
DE69933207D1 (de) Verbessertes verfahren zur herstellung von makroliden
DE69908824D1 (de) Verfahren zur herstellung von bisphenol-a
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE59808528D1 (de) Verfahren zur Herstellung von 3-Glycidyloxypropyltrialkoxysilanen
DE59907055D1 (de) Verfahren zur herstellung von tetrachlorkohlenstoffarmen phosgen
DE69935509D1 (de) Verfahren zur herstellung von durchscheinenden zahnersätzen
DE60239842D1 (de) Verfahren zur Herstellung von 10,11-dihydro-10-oxo-5h-dibenzoÄb,fÜazepin-5-carboxamid
ATA218299A (de) Verfahren zur herstellung von oxindolen
DE69939559D1 (de) Methode zur Beschleunigung der Schleimauflöserate
DE69927943D1 (de) Verfahren zur herstellung von cefpodoxim-proxetil diastereoisomeren
DE59902618D1 (de) Verfahren zur Herstellung von Arylhydrazinen
DE60039688D1 (de) Verfahren zur herstellung von uhrarmbandteilen
DE69936449D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE59909842D1 (de) Verfahren zur Herstellung von Selektivaustauschern
DE60010034D1 (de) Methode zur handhabung von 1,1,1,3,3-pentfluoropropan
DE69922786D1 (de) Methode zur behandlung der chronischen obstruktiven bronchopneumopathie
DE69917574D1 (de) Methode zur Immobilisierung von Verbindungen
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE50008921D1 (de) Verfahren zur herstellung von blockweichschaumpolyolen
DE69928206D1 (de) Verfahren zur Herstellung von S-Hydroxynitrillyasen
DE50000074D1 (de) Verfahren zur Herstellung von halogenierten 1,2-Disilaethanen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1374891

Country of ref document: EP

REN Ceased due to non-payment of the annual fee